Multitarget FAAH and COX inhibitors

The invention provides novel multitarget inhibitors of FAAH, COX-1 and/or COX-2. The invention concerns also with therapeutical application of the multitarget inhibitors in particular in the prevention and treatment of cancer.

Patent title Multitarget FAAH and COX inhibitors and therapeutical uses thereof
Thematic area Health
Ownership University of California, ISTITUTO ITALIANO DI TECNOLOGIA - sede di Genova, ALMA MATER STUDIORUM - UNIVERSITA' DI BOLOGNA
Inventors DAMIEN HABRANT, ANGELO FAVIA, MARCO DE VIVO, RITA SCARPELLI, MARCO MIGLIORE, DANIELE PIOMELLI, Andrea Cavalli
Protection Italy, Germany, France, Great Britain, Australia, Canada, USA, Japan
Licensing status Available for development agreements, option, license and other exploitation agreements
Keywords Anti-inflammatory drugs, Multitarget, Polypharmacology, FAAH, COX multitarget, Inhibitors, Cancer
Filed on 06 August 2012

Inflammatory pathologies afflict hundreds of millions of people worldwide. Yet the use of current therapies is limited by potentially serious side effects, such as gastric damage, kidney damage and increased risk of stroke.

Therefore, a need still exists for new therapeutically active compounds, which are effective in the treatment of inflammation and related conditions whose administration results in a reduced risk of side effects in humans.

The invention provides novel compounds that simultaneously inhibit the enzymes Fatty Acid Amide Hydrolase (FAAH), Cyclooxygenase-1 (COX-1) and/or Cyclooxygenase-2 (COX-2), and therapeutic uses of such compounds.

The compounds of the invention find application in the medical field, in the treatment of pathological conditions in which simultaneous inhibition of FAAH, COX-1 and/or COX-2 activities is desirable. The combined FAAH and COX-1 and/or COX-2 inhibitors are useful in the treatment of cancer and precancerous conditions and find additional applications in the treatment of inflammatory diseases, pain, eating disorders, anxiety and cardiovascular disorders.

Page published on: 23 March 2018